Linden Thomas Advisory Services LLC Purchases 96 Shares of Neurocrine Biosciences, Inc. $NBIX

Linden Thomas Advisory Services LLC lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the 2nd quarter, Holdings Channel reports. The fund owned 6,699 shares of the company’s stock after acquiring an additional 96 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Neurocrine Biosciences were worth $842,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in Neurocrine Biosciences in the first quarter worth $1,460,000. Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at $696,000. Wealth Enhancement Advisory Services LLC grew its position in shares of Neurocrine Biosciences by 229.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 19,107 shares of the company’s stock worth $2,467,000 after buying an additional 13,301 shares during the period. Golden State Wealth Management LLC grew its position in shares of Neurocrine Biosciences by 116.9% in the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after buying an additional 214 shares during the period. Finally, Integrated Wealth Concepts LLC increased its stake in shares of Neurocrine Biosciences by 167.2% in the 1st quarter. Integrated Wealth Concepts LLC now owns 7,233 shares of the company’s stock worth $800,000 after acquiring an additional 4,526 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.2%

NBIX stock opened at $144.00 on Monday. The stock’s 50 day simple moving average is $139.94 and its 200 day simple moving average is $128.02. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $154.61. The stock has a market capitalization of $14.28 billion, a PE ratio of 42.60, a price-to-earnings-growth ratio of 0.98 and a beta of 0.21.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million during the quarter, compared to analysts’ expectations of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company’s revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.63 earnings per share. On average, research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of the company’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the transaction, the director owned 514,596 shares in the company, valued at approximately $65,050,080.36. This represents a 17.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the topic of several research reports. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a research note on Thursday, July 10th. They set a “buy” rating and a $182.00 price objective on the stock. Needham & Company LLC boosted their price target on Neurocrine Biosciences from $161.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, September 22nd. Guggenheim upped their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Piper Sandler lifted their price objective on Neurocrine Biosciences from $154.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Finally, Royal Bank Of Canada increased their target price on Neurocrine Biosciences from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $164.32.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.